Transplanted hearts shift toward recipients' molecular age
A new Harvard preprint finds that transplanted hearts shift toward their recipients' molecular age. In mice, young hearts aged epigenetically in older hosts while old hearts looked younger in young hosts. Human biopsy and clinical data pointed the same way, with no clear aging of the recipients' own organs.
Key Takeaways
- Mouse heart grafts moved toward recipient epigenetic age within four to six months.
- Recipients' native heart, liver, and blood showed no consistent age shift from the graft.
- Gene expression, especially mitochondrial programs, tracked the recipient's age direction.
- Human biopsy clocks and one-year clinical records aligned with recipient-driven remodeling.
- Findings may expand older-donor use but question how long young organs stay young in old bodies.
What did the Harvard transplant study actually find?
Researchers at Harvard Medical School, reporting a not-yet-peer-reviewed preprint covered by Lifespan.io, transplanted hearts among young, middle-aged, and old C57BL/6 mice while leaving each recipient's own heart in place.
Four to six months later, three epigenetic clocks showed the graft's biological age shifting toward the host: young hearts in old mice looked older; old hearts in young mice looked younger. Corresponding author Vadim Gladyshev called recipient age the most striking influence on the transplanted heart's biological age.
RNA sequencing echoed that pattern. Young grafts in old recipients moved toward aging-linked expression; old grafts in young recipients moved toward longevity-intervention signatures. Mitochondrial energy programs were downregulated in the first case and upregulated in the second, relative to age-matched controls.
Does a transplanted heart change the rest of the body?
In this mouse design, the answer was largely no. Epigenetic ages of the native heart, liver, and blood showed no consistent effect from the graft. The systemic environment remodeled the transplant far more clearly than the transplant remodeled the body.
That asymmetry matters for longevity and biohacking strategies that treat organs as spare parts. Co-first author Jesse Poganik termed the pattern "biological age assimilation" and asked whether a rejuvenated heart would later assimilate an older host—pushing focus toward systemic interventions.
Do these findings apply to human heart transplant patients?
Yes, with caveats. The team reviewed 407 hospital transplants (2002–2022) and methylome-tested archived biopsies from 11 recipients—five with older donors, six with younger. Two of three clocks showed significant age-deviation differences between older-to-younger and younger-to-older groups; the third moved the same way without reaching significance.
About one year post-transplant, after adjusting for donor age and recipient sex, older recipients had higher heart rates, thinner left-ventricular posterior walls, and lower exercise capacity. Ejection fraction was not significantly tied to recipient age. Medications, fitness, and overall health could also explain those clinical gaps.
Gladyshev noted older donor organs may be more useful than assumed, pending long-term outcomes and irreversible structural damage. The flip side: young hearts may acquire older molecular profiles in older bodies, limiting organ-only rejuvenation unless the wider host is addressed too.